01953nas a2200337   4500000000100000008004100001653001100042653002800053653002200081653000900103653001000112653001500122653001100137653001000148653001500158653000900173653001600182653002000198653002800218653002900246100001300275700001400288700001100302700001700313245008000330856008400410300001100494490000800505520108800513022001401601       2006                            d10aFemale10aElephantiasis, Filarial10aAged, 80 and over10aAged10aAdult10aAdolescent10aHumans10aIndia10aLymphedema10aMale10aMiddle Aged10aQuality of Life10aSickness Impact Profile10aSkin Diseases, Parasitic1 aBabu B V1 aNayak A N1 aRath K1 aKerketta A S00aUse of the Dermatology Life Quality Index in filarial lymphoedema patients.  uhttps://academic.oup.com/trstmh/article-lookup/doi/10.1016/j.trstmh.2005.05.022  a258-630 v1003 a<p>The global programme to eliminate lymphatic filariasis has alleviation of suffering and disability as one of its components, and many efforts are being taken across the globe in this direction. However, there is no effective tool to assess the impact of these efforts on patients' quality of life and/or lessening of disability and suffering. The present paper reports the use of the Dermatology Life Quality Index (DLQI) in filarial lymphoedema patients. DLQI scores were collected from 203 patients recruited from a clinic and from the community. The DLQI score ranged from 0 to 17, and a mean score of 2.7 (SD 4.4) or 9.0% disability. This score is lower than many skin diseases reported so far. The scores for individual questions vary, but the degree of consistency of responses between questions is high. The differences between sexes, place of recruitment and grades of lymphoedema are not significant. Although the DLQI measures the quality of life due to lymphoedema, this study further warrants development of a good quality-of-life index for lymphoedema patients.</p>
  a0035-9203